DQAsomes as the Prototype of Mitochondria-Targeted Pharmaceutical Nanocarriers: An Update

Weissig, Volkmar; Lozoya, Maria; Yu, Nusem; D’Souza, Gerard G. M.

doi:10.1007/978-1-0716-1262-0_2

Cited by 7 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposome‐like vesicles modified with dequalinium (termed DQAsomes) have been investigated for mitochondrial delivery of nucleic acids. DQA possesses a positively charged quaternary ammonium and has been shown to prompt targeting and fusion with the negatively charged mitochondrial membrane (Bae et al, 2017 ; Lyrawati et al, 2011 ; Weissig et al, 2021 ). Bae et al developed DQA80somes for the transport of plasmid DNA encoding a GFP into mitochondria of HeLa cells (Figure 10 ) (Bae et al, 2017 ).…”

Section: Applications Of Nucleic Acid Therapiesmentioning

confidence: 99%

Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

Mollé

Smyth

Yuen

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Nucleic acid therapeutics can be used to control virtually every aspect of cell behavior and therefore have significant potential to treat genetic disorders, infectious diseases, and cancer. However, while clinically approved to treat a small number of diseases, the full potential of nucleic acid therapeutics is hampered by inefficient delivery. Nucleic acids are large, highly charged biomolecules that are sensitive to degradation and so the approaches to deliver these molecules differ significantly from traditional small molecule drugs. Current studies suggest less than 1% of the injected nucleic acid dose is delivered to the target cell in an active form. This inefficient delivery increases costs and limits their use to applications where a small amount of nucleic acid is sufficient. In this review, we focus on two of the major barriers to efficient nucleic acid delivery: (1) delivery to the target cell and (2) transport to the subcellular compartment where the nucleic acids are therapeutically active. We explore how nanoparticles can be modified with targeting ligands to increase accumulation in specific cells, and how the composition of the nanoparticle can be engineered to manipulate or disrupt cellular membranes and facilitate delivery to the optimal subcellular compartments. Finally, we highlight how with intelligent material design, nanoparticle delivery systems have been developed to deliver nucleic acids that silence aberrant genes, correct genetic mutations, and act as both therapeutic and prophylactic vaccines. This article is categorized under: Nanotechnology Approaches to Biology > Cells at the Nanoscale Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology‐Inspired Nanomaterials > Lipid‐Based Structures

show abstract

Section: Applications Of Nucleic Acid Therapiesmentioning

confidence: 99%

Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

Mollé

Smyth

Yuen

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…It is worth noting that cell-penetrating peptides and some nanostructures such as reversed micelles are internationalized via non-endocytic uptake pathways via pore-forming or fusion with the cell membrane, directly transporting their cargos into the cytoplasm ( 22 ). In addition to the delivery approaches discussed in this Special Issue, dequalinium-based liposome-like vesicles (DQAsomes) are a special type of nanostructures that specifically deliver bioacitve molecules to mitochondria ( 23 ).…”

Section: Cytoplasmic Delivery and Beyondmentioning

confidence: 99%

Editorial of Special Issue “Cytoplasmic Delivery of Bioactives”

2022

Pharm Res

View full text Add to dashboard Cite

Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques

Pegoraro,

Domingo-Ortí,

Conejos-Sánchez

et al. 2024

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

DQAsomes as the Prototype of Mitochondria-Targeted Pharmaceutical Nanocarriers: An Update

Cited by 7 publications

References 23 publications

Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

Editorial of Special Issue “Cytoplasmic Delivery of Bioactives”

Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques

Contact Info

Product

Resources

About